Financials data is unavailable for this security.
View more
Year on year Sun Pharmaceutical Industries Ltd grew revenues 10.51% from 438.86bn to 484.97bn while net income improved 13.01% from 84.74bn to 95.76bn.
| Gross margin | 79.15% |
|---|---|
| Net profit margin | 22.14% |
| Operating margin | 22.35% |
| Return on assets | 13.29% |
|---|---|
| Return on equity | 17.15% |
| Return on investment | 16.92% |
More ▼
Cash flow in INRView more
In 2024, Sun Pharmaceutical Industries Ltd increased its cash reserves by 100.83%, or 46.62bn. The company earned 121.36bn from its operations for a Cash Flow Margin of 25.02%. In addition the company used 6.90bn on investing activities and also paid 67.10bn in financing cash flows.
| Cash flow per share | 57.12 |
|---|---|
| Price/Cash flow per share | 31.20 |
| Book value per share | 288.06 |
|---|---|
| Tangible book value per share | 212.12 |
More ▼
Balance sheet in INRView more
| Current ratio | 2.67 |
|---|---|
| Quick ratio | 2.09 |
| Total debt/total equity | 0.0372 |
|---|---|
| Total debt/total capital | 0.0358 |
More ▼
Growth rates in INR
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 17.39% and 13.01%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked above the industry average relative to its peers.
| Div yield(5 year avg) | 1.04% |
|---|---|
| Div growth rate (5 year) | 37.47% |
| Payout ratio (TTM) | 10.85% |
| EPS growth(5 years) | 29.15 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 29.50 |
More ▼
